Surrozen reports Q3 net loss of $1.4M (vs $10.4M YoY); gets $10M BI milestone for SZN-413

Surrozen, Inc./DE

2024-Q3 EPS reported -$12.57 revenue$10,000,000

Net loss narrowed to $1.4M from $10.4M in Q3 2023; collaboration revenue $10.0M (BI milestone).
Cash $31.0M at Sep 30, 2024; plus $10M milestone received Oct 2024 from Boehringer Ingelheim.
Phase 1b SZN-043 in severe alcohol-associated hepatitis: cohort 1 completed; no SAEs, reduced bilirubin/MELD; PoC data expected H1 2025.
Nominated wholly-owned preclinical ophthalmology candidates SZN-8141/8143/113 targeting Fzd4; SZN-413 advancing with BI.
New TCGFB research collaboration for TGF-β antibodies in IPF; up to $6M plus equity warrant of 3.38M shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.